Genovior signed a MOU with JOWIN Biopharma

JOWIN is a new drug research and development company, focusing on the development of targeted cancer drugs and immunotherapy drugs. JOWIN is interested in GENOVIOR’s products and services that are related to peptide synthesis, active pharmaceutical ingredient (API) synthesis, and peptide-drug fusion technology in the lab scale and the whole production scale, and the injectable manufacturing capabilities. GENOVIOR will provide JOWIN with appropriate services to the client’s satisfaction and speed up products to the market.